Protocol VPROTOCOL V

RP&D

Protocol V — Personal Research Dosing & Reconstitution Reference

Jan 24, 2026protocol • stack • recovery • metabolism • peptides • veterans
← Back to RP&D

Personal reference file.
This is a transcription/format conversion of an existing private reference document.

Protocol V — Personal Research Dosing & Reconstitution Reference (v25 MASTER COMPLETE)

All prior reconstitution + unit-draw guidance preserved. Protocol blocks added after Notes for IGF + GH axis.

GH / IGF Axis

Hexarelin

Primary lane: Growth hormone pulse (GHRP)
Max effective dose: ~200–300 mcg
Vial size: 5 mg
Reconstitution: 3.0 mL total volume
Concentration: ~1,666 mcg/mL
Reference draws (U-100): 200 mcg = 12 units | 250 mcg = 15 units | 300 mcg = 18 units
Carb guidance: Avoid carbs 60–90 min before and ~45 min after

Notes:

  • Aggressive GH driver; consider shorter blocks vs long continuous runs.

Protocol:

  • Timing: Fasted AM or pre-bed
  • Frequency: 1–2× daily
  • Carbs: Avoid 60–90 min pre-dose
  • Cycle length: 4–6 weeks ON
  • Time OFF: 2–4 weeks OFF
  • Notes: Aggressive GH driver; can stack with CJC-1295 (No DAC); do not stack with GHRP-2; rotate to Ipamorelin for longer runs

GHRP-2

Primary lane: Growth hormone pulse (potent GHRP)
Max effective dose: ~200–300 mcg
Vial size: 5 mg
Reconstitution: 3.0 mL total volume
Concentration: ~1,666 mcg/mL
Reference draws (U-100): 200 mcg = 12 units | 250 mcg = 15 units | 300 mcg = 18 units
Carb guidance: Avoid carbs 60–90 min before and ~45 min after

Notes:

  • Stronger pulse than Hex for some; appetite/cortisol/prolactin effects can be more noticeable.

Protocol:

  • Timing: Fasted AM or pre-bed
  • Frequency: 1–2× daily
  • Carbs: Avoid 60–90 min pre-dose
  • Cycle length: 4–6 weeks ON
  • Time OFF: 2–4 weeks OFF
  • Notes: Strong GH pulse; appetite/cortisol effects possible; do not stack with Hexarelin; rotate rather than extend

Ipamorelin

Primary lane: Growth hormone pulse (low side-effect GHRP)
Max effective dose: ~200–300 mcg per pulse
Vial size: 5 mg
Reconstitution: 3.0 mL total volume
Concentration: ~1,666 mcg/mL
Reference draws (U-100): 200 mcg = 12 units | 250 mcg = 15 units | 300 mcg = 18 units
Carb guidance: Avoid carbs pre-dose; protein-only acceptable

Notes:

  • Good option for longer maintenance phases; often used after stronger blocks.

Protocol:

  • Timing: Fasted AM, post-workout, or pre-bed
  • Frequency: 1–2× daily
  • Carbs: Avoid pre-dose
  • Cycle length: 8–12 weeks ON
  • Time OFF: 2–4 weeks OFF
  • Notes: Lower side-effect option; ideal for longer maintenance; can follow Hex/GHRP-2 blocks

CJC-1295 (No DAC)

Primary lane: GH pulse amplification (GHRH)
Max effective dose: ~100–200 mcg per pulse (avoid pushing past ~300 mcg/injection)
Vial size: 5 mg
Reconstitution: 3.0 mL total volume
Concentration: ~1,666 mcg/mL
Reference draws (U-100): 100 mcg = 6 units | 150 mcg = 9 units | 200 mcg = 12 units
Carb guidance: Avoid carbs 60–90 min before; protein-only acceptable

Notes:

  • GHRH support; stack-friendly with GHRPs; improves pulse quality.

Protocol:

  • Timing: With GH pulses (AM / pre-bed)
  • Frequency: 1–2× daily
  • Carbs: Avoid 60–90 min pre-dose
  • Cycle length: 8–12 weeks ON
  • Time OFF: 4 weeks OFF
  • Notes: Enhances endogenous pulse quality; stack-friendly with Hex or Ipamorelin; not required for short aggressive cycles

Tesamorelin

Primary lane: Growth hormone pulse amplification (lipolysis + recovery)
Max effective dose: ~2 mg per dose
Vial size: 10 mg
Reconstitution: 1.0 mL total volume
Concentration: 10 mg/mL
Reference draw (U-100): 2 mg = 0.2 mL = 20 units
Carb guidance: Avoid carbs 90–120 min before and ~45–60 min after

Notes:

  • Timing discipline matters more than dose escalation.

Protocol:

  • Timing: PM / pre-bed
  • Frequency: Daily
  • Carbs: Avoid 90–120 min pre-dose and ~45 min post-dose
  • Cycle length: 12–16 weeks ON
  • Time OFF: 4–8 weeks OFF
  • Notes: Foundational GH signal; timing discipline > dose escalation

IGF-1 DES

Primary lane: Local hypertrophy signal (pre-workout)
Max effective dose: ~30–50 mcg
Vial size: 1 mg
Reconstitution: 3.0 mL total volume
Concentration: ~333 mcg/mL
Reference draw (U-100): 50 mcg = 0.15 mL = 15 units
Carb guidance: No carbs at injection; carbs later via post-workout LR3 window

Notes:

  • Typically paired with IGF-1 LR3 post-workout.

Protocol:

  • Timing: 10–15 minutes pre-workout
  • Frequency: Training days only
  • Carbs: Avoid until post-workout LR3 window
  • Cycle length: 4–6 weeks ON
  • Time OFF: Minimum 4 weeks OFF
  • Notes: Local signal; best paired with post-workout IGF-1 LR3; not a long-term standalone

IGF-1 LR3

Primary lane: Systemic hypertrophy signal (post-workout)
Max effective dose: ~40–80 mcg
*Female max effective dose: ~20–40 mcg
Vial size: 1 mg
Reconstitution: 3.0 mL total volume
Concentration: ~333 mcg/mL
Reference draw (U-100): 60 mcg = 0.18 mL = 18 units
Carb guidance: Use WITH carbs post-workout

Notes:

  • Systemic signal; best kept to training days during ON blocks.

Protocol:

  • Timing: Immediately post-workout
  • Frequency: Training days only
  • Carbs: Required post-dose
  • Cycle length: 4–6 weeks ON
  • Time OFF: Minimum 4 weeks OFF
  • Notes: Systemic anabolic signal; avoid continuous use

PEG-MGF

Primary lane: Satellite cell activation, delayed hypertrophy signal
Max effective dose: 2 mg
Protocol dose: 1 mg, 2× weekly
Vial size: 2 mg
Reconstitution: 2.0 mL total volume
Concentration: 1 mg/mL
Reference draw (U-100): 1 mg = 1.0 mL = 100 units
Carb guidance: Separate 2–4 hrs after IGF-1 LR3; avoid carbs for several hours post-dose

Notes:

  • Treat like a delayed amplifier, not a daily switch.

Protocol:

  • Timing: 2–4 hours post-workout
  • Frequency: 1 mg, 2× weekly
  • Carbs: Avoid for several hours post-dose
  • Cycle length: 4–6 weeks ON
  • Time OFF: 4+ weeks OFF
  • Notes: Delayed hypertrophy signal; do not overlap tightly with IGF timing; not daily

GH Strategy Note: Aggressive GH secretagogues (Hexarelin, GHRP-2) are best used in shorter blocks. Transition to Ipamorelin for longer maintenance phases to preserve sensitivity.

Repair / Inflammation / Joint

ARA-290 (Cibinetide)

Primary lane: Systemic inflammation control, tissue-protective signaling
Max effective dose: ~2–4 mg per dose
Frequency: Daily
Vial size: 10 mg
Reconstitution: 3.0 mL total volume
Concentration: ~3.33 mg/mL
Reference draw (U-100): 2 mg = 0.6 mL = 60 units
Carb guidance: Carbs irrelevant; fasted or fed

Notes:

  • Foundation anti-inflammatory signal; daily consistency aligns best with available human trial structures.

Protocol:

  • Timing: AM preferred
  • Frequency: Daily
  • Cycle length: 8–12 weeks ON
  • Time OFF: Minimum 4 weeks OFF
  • Carbs: Irrelevant (fasted or fed)

BPC-157

Primary lane: Tissue repair, gut integrity
Max effective dose: ~250–500 mcg per dose
Vial size: 10 mg
Reconstitution: 3.0 mL total volume
Concentration: ~3,333 mcg/mL
Reference draw (U-100): 250 mcg ≈ 8 units | 500 mcg ≈ 15 units
Carb guidance: Carbs irrelevant

Notes:

  • Pairs well with TB-500 or KPV depending on lane.
  • Human dosing data is limited; many frameworks are extrapolated.

Protocol:

  • Timing: AM preferred for gut focus; PM acceptable for tissue repair
  • Frequency: Daily or 1–2× daily (target-dependent)
  • Cycle length: 4–8 weeks ON
  • Time OFF: 2–4 weeks OFF
  • Carbs: Irrelevant

TB-500 (Thymosin Beta-4 fragment)

Primary lane: Systemic repair, angiogenesis, soft-tissue remodeling
Max effective range: ~2–5 mg per week
Frequency: 1–2× weekly (split optional)
Vial size: 5 mg
Reconstitution: 2.0 mL total volume
Concentration: 2.5 mg/mL
Reference draw (U-100): 1 mg = 0.4 mL = 40 units
Carb guidance: None

Notes:

  • Higher weekly totals don’t accelerate repair—just burn supply.
  • Human clinical evidence is limited; this is a conservative framework.

Protocol:

  • Timing: Any time of day
  • Frequency: 1–2× weekly
  • Cycle length: 6–8 weeks ON
  • Time OFF: 4–6 weeks OFF
  • Carbs: None

GHK-Cu (restored into Repair lane under TB-500)

NOTE: This entry is included here specifically so it sits with the rest of the repair/inflammation lane (under TB-500), before KPV.

Primary lane: Tissue repair, extracellular matrix signaling, skin/hair support
Max effective dose: 2–4 mg per day
Vial size: 100 mg
Reconstitution: 3.0 mL total volume
Concentration: ~33.3 mg/mL
Reference draw (U-100): 4 mg ≈ 12 units
Carb guidance: Carbs irrelevant

Notes:

  • Systemic mg-range reference (not topical).
  • Often positioned end-of-day for repair alignment.

Protocol:

  • Timing: PM preferred
  • Frequency: Daily
  • Cycle length: 8–12 weeks ON
  • Time OFF: 4–8 weeks OFF
  • Carbs: Irrelevant

KPV (Lys-Pro-Val)

Primary lane: Inflammation modulation (gut, skin, immune signaling)
Max effective range: ~300–500 mcg per day
Frequency: 1–2× daily
AM vs PM: Either; AM favored for gut-driven inflammation
Food rules: No strict carb rules; can be fasted or fed
Vial size: 10 mg
Reconstitution: 3.0 mL total volume
Concentration: ~3,333 mcg/mL
Reference draws (U-100): 300 mcg ≈ 9 units | 500 mcg ≈ 15 units

Notes:

  • More ≠ better; returns flatten rapidly above ~500 mcg/day.
  • Pairs well with ARA-290 and Cartilax; different lanes, minimal overlap.

Protocol:

  • Timing: AM or PM
  • Frequency: 1–2× daily
  • Cycle length: 8–12 weeks ON
  • Time OFF: 4 weeks OFF
  • Carbs: Irrelevant

Repair / Redox / Liver Support

Glutathione (Reduced GSH) — Injectable Reference

Primary lane: Redox buffering / liver stress support (marker recovery)
Vial size: 1200 mg
Carb guidance: No specific carb rule; timing relative to training matters more

Notes:

  • Treat like a short-lived redox pulse, not a permanent “fill the tank” solution.
  • “Liver protection” claims are often confounded by lab timing + hard training (AST/ALT can rise from lifting).
  • Best used during stress-window blocks, not year-round.

Protocol — Liver Marker Support (Non-Disease, Bodybuilder Transliteration)

Goal: Support normalization of AST/ALT during high-stress blocks (marker recovery), not disease treatment

Dose: 600 mg per exposure
Timing: Away from training window (avoid pre-workout / immediate post-workout)
Frequency: 2× per week (base) → 3× per week (if needed)
Cycle length: 4–6 weeks ON
Time OFF: Stop once markers normalize; reassess before repeating ]

Best reconstitution (easy draws): 1.0 mL
Concentration: 600 0.5 mg/mL

Reference draws (U-100):

  • 600 mg = 0.50 mL = 50 units

Key considerations (non-negotiable):

  • Lab standardization: No hard training 48–72 hours before bloodwork; same hydration; same time of day; similar diet pattern.
  • Do not use as a “once-weekly detox blast.”
  • If you want to judge signal, you need a controlled comparison: baseline → stress block → re-test → stop → re-test.

Escalation rule:

  • Run 600 mg 2×/week for 2–4 weeks with standardized labs.
  • If markers remain elevated AND labs were standardized → move to 600 mg 3×/week for the remainder of the block.
  • Avoid turning into daily chronic exposure unless under medical oversight.

What “success” looks like:

  • Faster return of liver markers toward baseline under controlled lab conditions.

Common failure modes:

  • Training too close to labs
  • Changing diet/sleep/alcohol simultaneously
  • Different lab timing/hydration state

Neuro / Sleep

Epitalon (Epithalon)

Primary lane: Circadian signaling / pineal regulation
Vial size: 10 mg
Carb guidance: Carbs irrelevant

Notes:

  • Best-supported lane is circadian/melatonin rhythm modulation (not proven telomere extension in living humans).
  • This is a regulator, not a sedative.
  • Sleep response is rarely linear with dose; overshooting can add noise.
  • Treat as a course with long washouts.

Protocol ① — Sleep / Circadian Reset (Evaluation Block)

Goal: Improve sleep onset, reduce night fragmentation, stabilize morning wake time

Transliteration for injectable research evaluation (conservative):

  • Dose range: 0.5–1.0 mg per day
  • Timing: Evening anchor (30–60 min pre-sleep)
  • Frequency: Daily during course
  • Cycle length: 20 days ON
  • Time OFF: 12–16 weeks OFF

Best reconstitution (easy draws): 2.0 mL
Concentration: 5 mg/mL (5,000 mcg/mL)

Reference draws (U-100):

  • 0.5 mg (500 mcg) = 0.10 mL = 10 units
  • 1.0 mg (1,000 mcg) = 0.20 mL = 20 units

Escalation rule (sleep-only):

  • Start at 0.5 mg/day for 10–14 days.
  • If no measurable improvement → move to 1.0 mg/day for the remainder of the course.
  • Avoid pushing beyond this for a sleep-only goal unless you have a clear reason and objective metrics.

Metrics to track (pick 3–5):

  • Sleep latency
  • Wake after sleep onset
  • Total sleep time
  • Resting HR / HRV trend
  • Morning alertness consistency

Common failure modes:

  • Late caffeine/stims, late heavy meals, inconsistent bedtime, late-night training intensity, alcohol.

Protocol ② — Longevity / Bioregulation Block (Exploratory)

Goal: Exploratory “maintenance” lane (pineal signaling + aging biology exploration)

Common research-style longevity course (community standard, not clinical guidance):

  • Dose range: 5–10 mg per day
  • Timing: Evening preferred
  • Frequency: Daily during course
  • Cycle length: 10–20 days ON
  • Time OFF: 4–6 months OFF

Best reconstitution (easy draws): 1.0 mL
Concentration: 10 mg/mL (10,000 mcg/mL)

Reference draws (U-100):

  • 5 mg = 0.50 mL = 50 units
  • 10 mg = 1.00 mL = 100 units

Notes:

  • Longevity claims exceed modern high-quality human outcome data; treat as exploratory.
  • Not an acute performance enhancer; the “feel” may be minimal if sleep is already tight.

Selank

Primary lane: Anxiolytic / stress modulation
Max effective dose: ~250–500 mcg
Vial size: 10 mg
Reconstitution: 3.0 mL total volume
Concentration: ~3,333 mcg/mL
Reference draw (U-100): 250 mcg ≈ 8 units | 500 mcg ≈ 15 units
Carb guidance: Carbs irrelevant

Notes:

  • Course-based anxiolytic peptide; not a stimulant.
  • Best used for tone stabilization rather than PRN spikes.

Protocol:

  • Timing: AM or early PM
  • Frequency: Daily during course
  • Cycle length: 10–21 days ON
  • Time OFF: 2–4 weeks OFF
  • Carbs: Irrelevant

Semax

Primary lane: Cognitive enhancement / neuroplasticity
Max effective dose: ~250–500 mcg
Vial size: 10 mg
Reconstitution: 3.0 mL total volume
Concentration: ~3,333 mcg/mL
Reference draw (U-100): 250 mcg ≈ 8 units | 500 mcg ≈ 15 units
Carb guidance: Carbs irrelevant

Notes:

  • Pro-cognitive and dopaminergic; more activating than Selank.
  • Overuse may worsen anxiety or overstimulation.

Protocol:

  • Timing: AM preferred (avoid late-day use)
  • Frequency: Daily during course
  • Cycle length: 5–14 days ON (up to ~21 days max)
  • Time OFF: 2–4 weeks OFF
  • Carbs: Irrelevant

DSIP (Delta Sleep-Inducing Peptide)

Primary lane: Sleep modulation
Max effective dose range: ~300–900 mcg
Vial size: 5 mg
Reconstitution: 2.0 mL total volume (recommended)
Concentration: 2.5 mg/mL
Reference draw (U-100): 300 mcg = 12 units | 900 mcg = 36 units
Carb guidance: Keep pre-bed intake clean; avoid heavy carbs near dosing
Storage note: Refrigerate after reconstitution (potency protection)

Notes:

  • Sleep-architecture modulator, not a sedative.
  • Effects may diminish with continuous long-term use.

Protocol:

  • Timing: 30–60 minutes pre-sleep
  • Frequency: Nightly during course
  • Cycle length: 5–14 days ON
  • Time OFF: 1–2+ weeks OFF
  • Carbs: Avoid heavy carbs near bedtime dose

Metabolic / Energy / Appetite

NAD⁺ (Nicotinamide Adenine Dinucleotide)

Primary lane: Cellular redox support, mitochondrial throughput, fatigue resistance
Vial size: 500 mg

Reconstitution (Protocol-Specific)

Protocol ② — Standard / Recovery & Performance

Reconstitution: 5.0 mL bacteriostatic water
Concentration: 100 mg/mL

Reference draws (U-100):

  • 100 mg = 1.0 mL (100 units)
  • 150 mg = 1.5 mL (150 units)
  • 200 mg = 2.0 mL (200 units)
  • 250 mg = 2.5 mL (250 units)
  • 500 mg = 5.0 mL (entire vial)

Protocol ① — Longevity / Maintenance

Reconstitution: 2.5 mL bacteriostatic water
Concentration: 200 mg/mL

Reference draws (U-100):

  • 250 mg = 1.25 mL (125 units)
  • 500 mg = 2.5 mL (250 units)

Carb guidance:
No special carbohydrate timing required. NAD⁺ performs best when baseline calories are adequate. Avoid running higher-dose phases during aggressive caloric restriction unless explicitly using Protocol ② for restoration.

Notes:

  • Standard cadence is often described as “2–3× weekly,” but cadence should match the goal, not the trend.
  • Most people respond better when they ramp exposure instead of starting at peak doses.
  • NAD⁺ does not scale linearly; higher weekly totals do not guarantee greater benefit.
  • Loss of “feel” over time usually indicates signal completion rather than failure.

Protocol (Standard) — Recovery & Performance Lane

  • Timing: Any consistent training or recovery window; avoid immediately pre-bed if stimulatory effects are noticed
  • Frequency: 2–3× per week
  • Dose (titrated):
    • Week 1: 100–150 mg per session
    • Week 2: 150–200 mg per session
    • Week 3+: 200–250 mg per session (if tolerated)
  • Weekly total: 400–750 mg (cap)
  • Cycle length: 6–8 weeks (default)
  • Time OFF: Transition to Protocol ① or reduce to ≤1× weekly
  • Notes: This is a phase, not a lifestyle. Benefits typically peak weeks 3–5.

Protocol (Longevity) — Maintenance Lane

  • Timing: Any consistent weekly anchor day
  • Frequency: 1–2× per week
  • Dose: 500 mg per session
  • Weekly total: 500–1000 mg
  • Cycle length: Long-term / ongoing
  • Time OFF: Not required when frequency remains low
  • Notes: Episodic repletion reduces adaptation risk and is intended for stability rather than acute sensation.

MOTS-C

Primary lane: Mitochondrial signaling, cellular energy
Vial size: 10 mg
Reconstitution: 2.0 mL total volume
Concentration: 5 mg/mL
Reference draw (U-100): 1 mg = 0.2 mL = 20 units
Carb guidance: Carbs irrelevant

Notes:

  • Human outcome protocols are limited; most evidence is preclinical/early translational.
  • Research often uses higher-magnitude pulsed designs aimed at adaptation.
  • This protocol is NOT the adaptation-focused pulse design; it is a daily-use extrapolation for energy/metabolic steadiness.

Protocol:

  • Protocol type: Exploratory / translational best-guess (daily use)
  • Timing: AM preferred
  • Frequency: Daily during course
  • Cycle length: 2–4 weeks ON
  • Time OFF: 4–8 weeks OFF
  • Carbs: Irrelevant

5-Amino-1MQ

Primary lane: NAD metabolism / energy signaling
Vial size: 10 mg
Reconstitution: 2.0 mL total volume
Concentration: 5 mg/mL
Reference draw (U-100): 3 mg = 0.6 mL = 60 units
Carb guidance: Carbs irrelevant

Note: If you specifically want a 30-unit draw for 3 mg, reconstitute 10 mg with 1.0 mL (then 3 mg = 30 units).

Notes:

  • *Upper limits are much higher; this is the daily energy protocol reference.
  • Research often uses higher-magnitude pulsed designs aimed at adaptation.
  • This protocol is NOT the adaptation-focused pulse design; it is a daily-use extrapolation for energy/metabolic steadiness.

Protocol:

  • Protocol type: Exploratory / translational best-guess (daily use)
  • Timing: AM preferred
  • Frequency: Daily during course
  • Cycle length: 2–4 weeks ON
  • Time OFF: 4+ weeks OFF
  • Carbs: Irrelevant
  • Daily energy protocol — 3 mg*

AOD-9604 (Fragment 176–191)

Primary lane: Metabolic signaling (non-GH axis)
Max effective dose: ~250–300 mcg/day
Vial size: 5 mg
Reconstitution: 2.0 mL total volume
Concentration: 2,500 mcg/mL
Reference draw (U-100): 250 mcg = 10 units | 300 mcg = 12 units
Carb guidance: No validated carb-timing requirement (fasted or fed)

Notes:

  • Human trial data exists but efficacy is inconsistent; keep expectations realistic.
  • This is not a GH replacement.

Protocol:

  • Timing: AM preferred (practical)
  • Frequency: Daily
  • Cycle length: 12–24 weeks ON
  • Time OFF: 4–6 weeks OFF
  • Carbs: No validated carb-timing requirement

Cagrilintide

Primary lane: Appetite regulation
Protocol reference: 0.2 mg weekly (evidence-aligned cadence)
Vial size: 10 mg
Reconstitution: 3.0 mL total volume
Concentration: 3.33 mg/mL
Reference draw (U-100): 0.2 mg = 0.06 mL = 6 units
Carb guidance: Carbs optional; GI tolerance matters

Notes:

  • Long half-life supports weekly cadence; most human-style use is long duration.
  • This is an appetite-regulation lane; monitor intake during performance phases.

Protocol:

  • Timing: Any; consistency > timing
  • Frequency: Weekly
  • Cycle length: Months (trial-style frameworks)
  • Time OFF: 8+ weeks OFF (assessment window)
  • Carbs: Optional

Retatrutide

Primary lane: Multi-agonist metabolic regulation
Vial size: 10 mg
Reconstitution: 2.0 mL total volume
Concentration: 5 mg/mL
Reference draw (U-100): 0.5 mg = 0.1 mL = 10 units
Carb guidance: Carbs optional; consistency > timing

Notes:

  • Evidence base is weekly dosing over long durations in human trials.
  • Appetite suppression is exposure/peak dependent; performance use may prefer smoother exposure profiles.

Protocol:

  • Protocol A (evidence-anchored): Weekly cadence aligned with human trials; long duration (months).
  • Protocol B (performance extrapolation): Daily dose-fractionated administration where total weekly exposure equals the weekly protocol, distributed evenly to reduce peak-driven appetite suppression while supporting insulin sensitivity during surplus phases.
  • Cycle length (performance extrapolation): 8–16 weeks ON
  • Time OFF (performance extrapolation): 4+ weeks OFF (assessment window)
  • Carbs: Optional; prioritize GI tolerance and consistent timing

Pigmentation / Cosmetic

Melanotan-1

Primary lane: Pigmentation
Max effective dose: 250–500 mcg
Vial size: 10 mg
Reconstitution: 3.0 mL total volume
Concentration: ~3,333 mcg/mL
Reference draws (U-100): 250 mcg ≈ 8 units | 500 mcg ≈ 15 units
Carb guidance: Carbs irrelevant

Notes:

  • Clinical analog exists as afamelanotide (implant) for specific medical indications; cosmetic protocols are non-clinical.
  • Often considered lower side-effect burden than MT-2, but still non-regulated for cosmetic use.

Protocol:

  • Timing: PM preferred (practical)
  • Frequency: 2–7× weekly during evaluation block
  • Cycle length: 2–4 weeks ON
  • Time OFF: 8–12 weeks OFF
  • Carbs: Irrelevant

Melanotan-2

Primary lane: Pigmentation / libido
Max effective dose: 250–500 mcg
Vial size: 10 mg
Reconstitution: 3.0 mL total volume
Concentration: ~3,333 mcg/mL
Reference draws (U-100): 250 mcg ≈ 8 units | 500 mcg ≈ 15 units
Carb guidance: Carbs irrelevant

Safety / Risk Notes:

  • High-risk, non-clinical compound with documented adverse events.
  • Systemic toxicity reported.
  • Rhabdomyolysis reported; renal dysfunction/acute kidney injury reported.
  • Priapism reported.
  • No controlled long-term safety trials for cosmetic use; sourcing/contamination risk is real.

Notes:

  • Not a performance compound; risk-benefit is poor in many contexts.

Protocol:

  • Protocol status: Not recommended as a standard protocol due to adverse event profile.
  • If evaluated at all: keep blocks short, minimize exposure, and use long washouts.
  • Cycle length: ≤2 weeks ON (evaluation only)
  • Time OFF: 12+ weeks OFF
  • Carbs: Irrelevant
Explore more RP&D →